EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mediating role of chiro-inositol metabolites on the effects of HLA-DR-expressing CD14 + monocytes in inflammatory bowel disease

Leichang Zhang, Pan Shen, Wei Ge, Wu Liao, Qinghua Luo, Chaofeng Li, Chuanyu Zhan, Xiao Yuan, Xiaonan Zhang, Xiaojun Yan

BMC Gastroenterology · 2024

DOI: 10.1186/s12876-024-03271-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMC Gastroenterology, 2024. Verfasst von Leichang Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Jiangxi College of TCM, Nanchang, Jiangxi, 330000, China. Hauptthemen laut MEDLINE: Monocytes, Lipopolysaccharide Receptors, Inflammatory Bowel Diseases, HLA-DR Antigens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory bowel disease (IBD), a chronic inflammatory condition, is caused by several factors involving aberrant immune responses. Genetic factors are crucial in IBD occurrence. Mendelian randomization (MR) can offer a new perspective in understanding IBD’s genetic background.

Methods

Single nucleotide polymorphisms (SNPs) were considered instrumental variables (IVs). We analyzed the relationship between 731 immunophenotypes, 1,400 metabolite phenotypes, and IBD. The total effect was decomposed into indirect and direct effects, and the ratio of the indirect effect to the total effect was calculated.

Results

We identified the causal effects of HLA-DR-expressing CD14 + monocytes on IBD through MR analysis. The phenotype “HLA-DR expression on CD14 + monocytes” showed the strongest association among the selected 48 immune phenotypes. Chiro-inositol metabolites mediated the effect of CD14 + monocytes expressing HLA-DR on IBD. An increase in Chiro-inositol metabolites was associated with a reduced risk of IBD occurrence, accounting for 4.97%.

Conclusion

Our findings revealed a new pathway by which HLA-DR-expressing CD14 + monocytes indirectly reduced the risk of IBD occurrence by increasing the levels of Chiro-inositol metabolites. The results provided a new perspective on the immunoregulatory mechanisms underlying IBD, laying a theoretical foundation for developing new therapeutic targets in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MonocytesLipopolysaccharide ReceptorsInflammatory Bowel DiseasesHLA-DR AntigensPolymorphism, Single NucleotideInositolHumansMendelian Randomization AnalysisPhenotypeImmunophenotypingFemaleMale

Stichwörter der Autor:innen

Causal inferenceImmunityInflammatory bowel diseaseMendelian randomization analysisMetabolite

Substanzen

Lipopolysaccharide ReceptorsHLA-DR AntigensInositolCD14 protein, human

Autor:innen und Institutionen

  • Affiliated Hospital of Jiangxi College of TCM, Nanchang, Jiangxi, 330000, China.
  • Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, 330000, China.
  • Affiliated Hospital of Jiangxi College of TCM, Nanchang, Jiangxi, 330000, China. 82598907@qq.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, L., Shen, P., Ge, W., Liao, W., Luo, Q., Li, C., Zhan, C., Yuan, X., Zhang, X., & Yan, X. (2024). Mediating role of chiro-inositol metabolites on the effects of HLA-DR-expressing CD14 + monocytes in inflammatory bowel disease. BMC Gastroenterology. https://doi.org/10.1186/s12876-024-03271-2

Vancouver

Zhang L, Shen P, Ge W, Liao W, Luo Q, Li C, et al. Mediating role of chiro-inositol metabolites on the effects of HLA-DR-expressing CD14 + monocytes in inflammatory bowel disease. BMC Gastroenterology. 2024. doi:10.1186/s12876-024-03271-2

BibTeX
@article{Zhang2024,
  author = {Zhang, Leichang and Shen, Pan and Ge, Wei and Liao, Wu and Luo, Qinghua and Li, Chaofeng and Zhan, Chuanyu and Yuan, Xiao and Zhang, Xiaonan and Yan, Xiaojun},
  title = {Mediating role of chiro-inositol metabolites on the effects of HLA-DR-expressing CD14 + monocytes in inflammatory bowel disease},
  journal = {BMC Gastroenterology},
  year = {2024},
  doi = {10.1186/s12876-024-03271-2}
}
Kostenlos starten →